PMID- 15932730
OWN - NLM
STAT- MEDLINE
DCOM- 20051129
LR  - 20181201
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 85
IP  - 10
DP  - 2005 Mar 16
TI  - [The effect of carvedilol on apoptosis gene PDCD5 expression in chronic heart 
      failure patients].
PG  - 676-8
AB  - OBJECTIVE: To observe the changes of serum PDCD5 antibody in chronic ischemic 
      heart failure patients and the effect of carvedilol treatment. METHODS: Twenty 
      chronic ischemic heart failure patients, 11 males and 9 females, aged 58 +/- 13, 
      with the left ventricular ejection fraction (LVEF) < 45% by echocardiography and 
      New York Heart Association (NYHA) cardiac function classification II-III, were 
      treated with carvedilol for 6 months with a target dosage of 50 mg/d. The serum 
      PDCD5 antibody was tested by ELISA before and after carvedilol treatment and 
      compared with those of 20 healthy persons. RESULTS: The A value of PDCD5 antibody 
      in the heart failure patients was 3.5 +/- 1.4, significantly higher that in than 
      healthy persons (1.9 +/- 1.0, P < 0.01). After treatment of carvedilol, the A 
      value of PDCD5 antibody in the heart failure patients decreased to 2.5 +/- 1.2 (P 
      < 0.05). In 6 months maintenance treatment, 14 (70%) patients reached the dosage 
      50 mg/d, 4 (20%) reached 25 mg/d, and 2 (10%) reached 12.5 mg/d. Five patients 
      (25%) had side effect such as dizziness, nausea and cough, one patient (5%) was 
      hospitalized for 3 weeks because of heart failure, no patient died. After 
      treatment of carvedilol, the NYHA degree increased by 0.3 (P < 0.05), LVEF 
      increased from 35.5% +/- 7.8% to 42.7% +/- 9.6% (P < 0.05), left ventricular 
      end-diastolic diameter decreased 5.3 mm (P < 0.05), and left ventricular 
      end-systolic diameter decreased by 8.1 mm (P < 0.01). CONCLUSION: The titer of 
      apoptosis gene PDCD5 antibody in the serum of chronic ischemic heart failure 
      patients are higher, which shows apoptosis and treatment of carvedilol 
      significantly decreases its titer.
FAU - Wu, Yan
AU  - Wu Y
AD  - People's Hospital, Peking University, Beijing 100044, China.
FAU - Nie, Xiao-Yun
AU  - Nie XY
FAU - Hu, Da-Yi
AU  - Hu DY
FAU - Lu, Pi-Neng
AU  - Lu PN
FAU - Zhang, Guo-Qiang
AU  - Zhang GQ
FAU - Luo, Lan
AU  - Luo L
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Adrenergic alpha-Antagonists)
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Apoptosis Regulatory Proteins)
RN  - 0 (Carbazoles)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (PDCD5 protein, human)
RN  - 0 (Propanolamines)
RN  - 0K47UL67F2 (Carvedilol)
SB  - IM
MH  - Adrenergic alpha-Antagonists/therapeutic use
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Adult
MH  - Aged
MH  - *Apoptosis
MH  - Apoptosis Regulatory Proteins/*biosynthesis/genetics
MH  - Carbazoles/*therapeutic use
MH  - Carvedilol
MH  - Female
MH  - Heart Failure/*drug therapy/genetics/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Proteins/*biosynthesis/genetics
MH  - Propanolamines/*therapeutic use
MH  - Prospective Studies
EDAT- 2005/06/04 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/06/04 09:00
PHST- 2005/06/04 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/06/04 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2005 Mar 16;85(10):676-8.